Blinded NO Treatment Received



Indications and Reactions:

Role Indications Reactions
Primary
Chronic Obstructive Pulmonary Disease 64.6%
Hypertension 8.5%
Cardiac Failure 3.8%
Angiodysplasia 2.3%
Attention Deficit/hyperactivity Disorder 2.3%
Cystic Fibrosis 2.3%
Myocardial Ischaemia 2.3%
Pseudomonas Infection 2.3%
Angina Pectoris 1.5%
Asthma 1.5%
Polycystic Liver Disease 1.5%
Cerebral Infarction 0.8%
Dizziness 0.8%
Dry Eye 0.8%
Gastric Ulcer 0.8%
Gastritis 0.8%
Gastritis Prophylaxis 0.8%
Gastrooesophageal Reflux Disease 0.8%
Gout 0.8%
Hypothyroidism 0.8%
Chronic Obstructive Pulmonary Disease 26.3%
Acute Left Ventricular Failure 5.3%
Arterial Occlusive Disease 5.3%
Cardiopulmonary Failure 5.3%
Coronary Artery Disease 5.3%
Depression 5.3%
Haemoptysis 5.3%
Hepatic Cancer 5.3%
Hepatic Enzyme Increased 5.3%
Hypoglycaemia 5.3%
Infective Pulmonary Exacerbation Of Cystic Fibrosis 5.3%
Ischaemic Stroke 5.3%
Lung Neoplasm 5.3%
Prostate Cancer 5.3%
Pyelonephritis 5.3%
Secondary
Cardiac Failure 28.7%
Cardiac Failure Chronic 17.4%
Hypertension 6.3%
Breast Cancer Metastatic 6.1%
Cardiovascular Disorder 5.6%
Chronic Obstructive Pulmonary Disease 4.6%
Cardiac Failure Congestive 3.7%
Tuberous Sclerosis 3.3%
Cardiovascular Event Prophylaxis 3.2%
Prophylaxis 2.8%
Diabetes Mellitus 2.6%
Coronary Artery Disease 2.3%
Type 2 Diabetes Mellitus 2.1%
Juvenile Arthritis 2.0%
Atrial Fibrillation 1.9%
Myocardial Ischaemia 1.8%
Renal Transplant 1.7%
Multiple Myeloma 1.4%
Angina Pectoris 1.3%
Hyperlipidaemia 1.2%
Concomitant Disease Progression 16.6%
Cardiac Failure 8.9%
Pneumonia 8.3%
Hypotension 6.8%
Renal Failure Acute 6.6%
Disease Progression 6.2%
Urinary Tract Infection 5.1%
Vomiting 4.0%
Chronic Obstructive Pulmonary Disease 3.8%
Anaemia 3.6%
Dyspnoea 3.6%
Syncope 3.6%
Dehydration 3.4%
Coronary Artery Disease 3.2%
Ventricular Tachycardia 3.2%
Dizziness 3.0%
Renal Impairment 2.8%
Cardiac Failure Congestive 2.5%
Renal Failure 2.5%
Atrial Fibrillation 2.3%
Concomitant
Cardiac Failure 31.3%
Cystic Fibrosis 18.8%
Hypertension 18.8%
Pseudomonas Infection 18.8%
Asthma 12.5%
Alanine Aminotransferase Increased 50.0%
Bronchopneumonia 50.0%
Interacting
Astrocytoma, Low Grade 50.0%
Epilepsy 50.0%
Complex Partial Seizures 50.0%
Drug Interaction 50.0%